CARLSBAD, Calif., May 14, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that Ion PGM™ now significantly outperforms its competitor on the major performance metrics for benchtop sequencing. It offers the simplest and fastest workflow, lowest cost-per-sample, and highest sensitivity for multiple basic and clinical research applications—all on a sequencer that is a fraction of the cost of the alternative.
The performance gains are the result of upfront sample prep automation, new Ion PGM™ semiconductor chips that deliver up to 10-fold greater throughput, and improved variant-calling software. Life Technologies is also shipping a redesigned Ion PGM™ Sequencer priced 30 percent less than the original, a savings realized by leveraging the significant economies of scale in electronics manufacturing. See http://www.lifetechnologies.com/pgm for more.
"Ion PGM™ and Ion AmpliSeq™ technology have transformed gene panel sequencing by making it faster, simpler, and more accessible, and that's made us the number-one benchtop sequencer in the market," said Maneesh Jain, VP of Marketing at Ion Torrent. "Today's new advances make gene panel sequencing on the Ion platform superior to our competitor by every major performance metric."
Ion AmpliSeq™ gene panels enable scientists to amplify over 6,000 targets in a single tube in 3.5 hours with only 10 ng of input sample. In the past 18 months, over 1,500 scientists have designed more than 5,000 different Ion AmpliSeq™ gene panels, indicating broad adoption of this game-changing technology.
Simplest and fastest* workflow: automated solution for gene panel sequencing
Together, Ion AmpliSeq™ gene panels and the Ion PGM™ System deliver the industry's simplest and fastest gene panel workflow. The upcoming Ion Chef™ System provides a fully automated solution for sample prep up front of the Ion PGM™ and Ion Proton™ sequencers. This enables a sample-to-result workflow that far outperforms our competitor, with a more than two-fold advantage in turnaround time, hands-on time, and number of pipetting steps.
Best accuracy: up to 100 percent sensitivity for multiple gene panels
In the past, researchers transitioning from studying individual genes and mutations, to sequencing gene panels were seriously challenged by identifying all the mutations present in the sample. Ion AmpliSeq™ technology coupled with the new, tunable Torrent Suite v3.6 software provides up to 100 percent sensitivity for multiple panels, enabling researchers to see their variants of interest. Additionally, the new Ion Reporter 1.6 Software enables researchers to rapidly annotate and filter variants, completing the gene panel design and analysis workflow.
Two research groups that used an Ion AmpliSeq™ Community panel for sequencing the BRCA1 and BRCA2 genes recently showed the accuracy and sensitivity of Ion PGM™ technology. The genes, which have been implicated in hereditary breast and ovarian cancers, are often difficult to sequence because there are many mutations scattered throughout the gene, including many truncating mutations and homopolymer regions.
"We've moved various genetic tests to the Ion PGM™ System," said Dr. Jose Carlos Machado, a principal investigator at the Institute of Molecular Pathology and Immunology Faculty of Medicine at the University of Porto in Portugal (IPATIMUP) who is helping develop the panel. "Analysis of the data resulted in an experimental approach with a specificity of 99%, and an analytical sensitivity of 99% with a confidence of 99%. The reduction in hands-on time has released the technical laboratory staff to other aspects of running the laboratory."
Dr. Machado has been working with researchers from the Radboud University Nijmegen Medical Centre, in The Netherlands, including Dr. Marcel Nelen.
"We used Ion AmpliSeq™ BRCA1 & BRCA 2 Community Panel design and the Ion PGM™ to sequence 65 difficult samples and haven't missed any mutations," said Dr. Nelen. "So our data shows Sanger sequencing sensitivity and that homopolymer regions have been tackled."
Lowest cost-per-sample for gene panel sequencing: new Ion PGM™ chips
The second-generation Ion 314 Chip throughput will jump up to 100 Mb throughput from its original 10 Mb throughput, while the cost will remain at only $99 USD. The Ion 316 Chip will produce up to 1 Gb throughput, compared to its original 100 Mb throughput, and the Ion 318 Chip will produce as much as 2 Gb throughput, compared to its original 1 Gb throughput. As a result, researchers can sequence a typical 200-amplicon/target project for as low as $100 USD per sample.
"Previously we sequenced three samples on the original Ion 314 chips," said Dr. Jose Luis Costa, from IPATIMUP, who is also working with an Ion AmpliSeq™ Community panel design for BRCA1 & BRCA2. "With the second-generation Ion 314 chips, we can increase to up to five samples per chip. We're also seeing longer reads and higher read quality--all in all, results point to better quality sequencing at higher run throughput."
Unmatched accessibility: compelling economics enable sequencing for all
The redesigned Ion PGM™ System is now available with two options: a semi-automated system that is half the price of our competitor's system and a fully automated system that is 20 percent less.
Ion PGM and Ion Proton sequencers are For Research Use Only. Not for use in diagnostic procedures
*Based on head-to-head comparison of comparable gene panels.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies
has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the
like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact :
SOURCE Life Technologies Corporation